共 158 条
[1]
Griffiths CEM(2021)Psoriasis Lancet 397 1301-1315
[2]
Armstrong AW(2015)Psoriasis Lancet 386 983-994
[3]
Gudjonsson JE(2013)Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br J Dermatol 168 412-421
[4]
Barker J(2012)Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 366 1190-1199
[5]
Boehncke WH(2013)Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Lancet 382 780-789
[6]
Schon MP(2008)Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 106-115
[7]
Papp KA(2012)IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis J Allergy Clin Immunol 130 145-154 e149
[8]
Langley RG(2009)The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo Nat Immunol 10 314-324
[9]
Sigurgeirsson B(2017)Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial J Am Acad Dermatol 76 405-417
[10]
Abe M(2017)Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial J Am Acad Dermatol 76 418-431